ArticleOncotarget2018

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Maria Quanz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.